

File 351:DERWENT WPI 1963-1997/UD=9718;UA=9715;UM=9710

(c)1997 Derwent Info Ltd

*File 351: **** Newly enhanced single file is now ONLINE!! ****
See HELP NEWS 351 for more information.

Set Items Description

--- -----
?t 011171839/9

011171839/9
DIALOG(R)File 351:DERWENT WPI
(c)1997 Derwent Info Ltd. All rts. reserv.

011171839

WPI Accession No: 97-149764

XRAM Accession No: C97-047964

Cancer metastasis inhibitor - comprises eicosa-pentanoic acid and docosa-hexaenoic acid

Patent Assignee: SAGAMI CHEM RES CENTRE (SAGA)

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
JP 9025231	A	19970128	JP 95177171	A	19950713	A61K-031/20	199714 B

Priority Applications (No Kind Date): JP 95177171 A 19950713

Patent Details:

Patent	Kind	Lan	Pg	Filing Notes	Application	Patent
JP 9025231	A		4			

Abstract (Basic): JP 9025231 A

Cancer metastasis inhibitor comprises eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and/or their deriv. The inhibitor is formulated into powder, granules, capsules, tablets, syrup or elixirs for oral admin.; or injection for parenteral admin.. The amt. of EPA or DHA is 1-90 wt.%, pref. 10-80 wt.%..

USE/ADVANTAGE - The inhibitor is effective against metastasis of cancer, esp., lung cancer. The daily dosage of EPA or DHA is 0.1-5g, pref. 0.5-2.5 g. The inhibitor has low toxicity and shows its effect significantly even with a small amt..

In an example, the Co26 metastatic strains were prepd. from CDF1 mice (22 g, 5 week old) by intravenous injection of Co26 cell and subcutaneous transplantation of lung metastasis on the backs of mice. After subcutaneous injection of Co26 metastatic strain cells (1 ml) on the back of mice, the following ethyl esters (0.1 ml each) were administered orally for 5 days/week over 4 weeks to A-E gp.; oleic acid to (A gp.), linoleic acid to (b gp.) arachidonic acid to (c gp.) EPA to (D gp.) and DHA to (E gp.). 31 days later, counted by Mann-Whitney U-test. The number of lung metastasis of A gp. was 21 out of 13 mice, that of B gp. was 26.5 out of 12 mice, that of C gp. was 19.0 out of 11 mice, that of D gp. was 1.40 out of 12 mice and that of gp. was 9.0 out of 11 mice. The results showed that E gp. (DHA gp.) and D gp. (EPA gp.) had significant lung metastasis inhibitory effects.

Dwg.0/0

Title Terms: CANCER; METASTASIS; INHIBIT; COMPRISE; EICOSA; PENTANOIC; ACID
; DOCOSA; HEXA; ENOIC; ACID

Derwent Class: B05

International Patent Class (Main): A61K-031/20

International Patent Class (Additional): A61K-031/23

File Segment: CPI

Manual Codes (CPI/A-N): B10-C04E; B12-M07; B12-M11; B14-H01B

?t 010985155/9

010985155/9

DIALOG(R)File 351:DERWENT WPI

(c)1997 Derwent Info Ltd. All rts. reserv.

010985155

WPI Accession No: 96-482104

XRAM Accession No: C96-150674

Tranquilliser contg. docosahexaenoic acid - has ataractic effect without
side effects

Patent Assignee: FUJI YAKUHHIN KK (FUJY); SAGAMI CHEM RES CENTRE (SAGA)

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
JP 8245378	A	19960924	JP 9549521	A	19950309	A61K-031/20	199648 B

Priority Applications (No Kind Date): JP 9549521 A 19950309

Patent Details:

Patent	Kind	Lan	Pg	Filing Notes	Application	Patent
JP 8245378	A		5			

Abstract (Basic): JP 8245378 A

Tranquilliser contains docosahexaenoic acid (DHA).

Tranquilliser pref. contains 5-100 (20-100) wt. % DHA (as free acid).

ADVANTAGE - The tranquillizer has an ataractic effect (esp. in stress)
without side effects.

In an example, to DHA ethyl ester (purity of at least 95 %),
alpha-tocopherol (0.5 wt. %) was added and the oily substance was charged
into gelatin soft capsules to give a soft capsule prepn. Ataractic effect
was estimated by PF-study (a type of psychological test). Students were
divided into two gps. Reference capsules (soybean oil 97 %, fish oil 3 %, DGA content: 0.5 %) and DHA capsules (fish oil, DHA content: 49.3 %) were
administered to Gp. 1 (n = 19) and Gp. 2 (n = 22), respectively by double
blind experiment for 3 months. PF-study was carried out at the beginning
and the end of admin. The changes in E minus under bar E % (indication of
immature aggression) and (MA) plus under bar I % (indication of sociality
and mental development) were observed. It is evident that an ataractic
effect is obtd. by admin. of DHA capsule.

Dwg.0/2

Title Terms: TRANQUILLISER; CONTAIN; DOCOSA; HEXA; ENOIC; ACID; ATARACTIC;
EFFECT; SIDE; EFFECT

Derwent Class: B05

File 347:JAPIO OCT 1976-1996/DEC. (UPDATED 970505)

(c) 1997 JPO & JAPIO

*File 347: Records current through Kokai Number 08-340700

Set Items Description

--- -----

?t 05208491/9

05208491/9

DIALOG(R)File 347:JAPIO

(c) 1997 JPO & JAPIO. All rts. reserv.

05208491

PRODUCTION OF TAXANE-TYPE DITERPENE

PUB. NO.: 08-163991 [JP 8163991 A]f

PUBLISHED: June 25, 1996 (19960625)

INVENTOR(s): YUKIMUNE TAKAHITO
HARA YASUHIRO

APPLICANT(s): MITSUI PETROCHEM IND LTD [000588] (A Japanese Company or Corporation), JP (Japan)

APPL. NO.: 06-312258 [JP 94312258]

FILED: December 15, 1994 (19941215)

INTL CLASS: [6] C12P-013/02; A61K-031/21; A61K-031/335; C12P-013/02;
C12R-001/91

JAPIO CLASS: 14.5 (ORGANIC CHEMISTRY -- Microorganism Industry); 14.4
(ORGANIC CHEMISTRY -- Medicine)

JAPIO KEYWORD:R051 (PHARMACEUTICALS -- Anti-cancer Agents)

ABSTRACT

PURPOSE: To obtain a taxane-type diterpene compound useful for a medicine, etc., of ovarian cancer, breast cancer and lung cancer, etc., in a high productivity by culturing tissue or cell, etc., of a plant producing a taxane-type diterpene in a medium containing fatty acids and recovering a product from the resultant cultured material.

CONSTITUTION: A tissue and/or cell of a plant (e.g. *Taxus brevifolia* NUTT) producing taxane-type diterpene (e.g. taxol, et.) is cultured in a medium containing 10-22C fatty acids such as oleic acid, linoleic acid, linolenic acid, arachidonic acid, capric acid, decenoic acid, lauric acid, dodecenoic acid, myristic acid, palmitic acid, stearic acid, eicosapentaenoic acid or docosahexaenoic acid in a concentration of 0.01-1000.mu.M. The object taxane-type diterpene useful for a remedy of ovarian cancer, breast cancer and lung cancer, etc., is obtained in a high productivity by recovering the taxane-type diterpene from the resultant cultured material.

?t 05071510/9

05071510/9

DIALOG(R)File 347:JAPIO

(c) 1997 JPO & JAPIO. All rts. reserv.